The cash balance at 31 March 2011 was $20.1m compared to $19.7m at 31 December 2010.

The Operating & Investing cash outflow of $1.6m for the quarter includes the costs of the fully enrolled phase 2 study assessing VivaGel^® as a treatment for bacterial vaginosis. Financing cash inflows of $2.0m included proceeds from the exercise of share options during the quarter.